Two prior trials (NCT03023423 and NCT03367819) have thus far evaluated the efficacy of the CD38 inhibitors isatuximab and daratumumab, respectively, in combination with PD-1/PD-L1 inhibitors in NSCLC but did not achieve satisfactory results. Here, CD38 is linked to non-small cell lung carcinoma.